Skip to content
10-K

Annual Report

KINNATE BIOPHARMA INC.

0001140361-23-011846

← back to feed
Filed
Mar 15, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 10, 2023 46.57M sh
Shares Diluted FY 2022 · Dec 31, 2021 43.6M sh
Capex FY 2022 · Dec 31, 2021 $769K
Operating Cash Flow FY 2022 · Dec 31, 2021 −$71.07M
Short Term Investments FY 2022 · Dec 31, 2021 $103.36M
Cash And Equivalents FY 2022 · Dec 31, 2021 $116.1M
Stockholders Equity FY 2022 · Dec 31, 2021 $319.48M
Current Liabilities FY 2022 · Dec 31, 2021 $12.39M
Total Liabilities FY 2022 · Dec 31, 2021 $12.39M
Current Assets FY 2022 · Dec 31, 2021 $258.69M
Total Assets FY 2022 · Dec 31, 2021 $366.86M
Eps Diluted FY 2022 · Dec 31, 2021 −$2.06
Eps Basic FY 2022 · Dec 31, 2021 −$2.06
Sga Expense FY 2022 · Dec 31, 2021 $22.95M
Rd Expense FY 2022 · Dec 31, 2021 $67.17M
Net Income FY 2022 · Dec 31, 2021 −$89.76M
Operating Income FY 2022 · Dec 31, 2021 −$90.11M